Dr. Adys Mendizabal, MD

Dr. Mendizabal practices at UCLA Neurology Group Practice in Los Angeles, California.

Dr. Mendizabal's NPI, 1649632787, was assigned on March 28, 2016. Dr. Mendizabal graduated from Lewis Katz School of Medicine in 2016. Dr. Mendizabal's California license number on file is A167052.

Dr. Mendizabal's primary practice is UCLA Neurology Group Practice, at 5767 W Century Blvd, Los Angeles, CA 90045 in Los Angeles County. The practice phone is (310) 794-1195.

Dr. Mendizabal's primary practice is UCLA Neurology Group Practice in Los Angeles, California. Dr. Mendizabal is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Neurology. Dmand AI also links Dr. Mendizabal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mendizabal practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Mendizabal's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Mendizabal is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Mendizabal's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists parkinson's disease and thoracic spine disorders among the conditions Dr. Mendizabal treats.

CMS data shows 80 Medicare services from Dr. Mendizabal across 2 procedure codes in 2024, for 28 Medicare patients. Medicare paid $5,597 for them. Every service was in an office.

CMS counts 28 Medicare patients who saw Dr. Mendizabal in 2024. 57% of them have high cholesterol, and 50% have depression. 54% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mendizabal's median patient age at 54, with 53% women.

In 2024, Dr. Mendizabal wrote 270 Medicare Part D claims for 28 patients. 77% of them were for generic drugs. CMS names the drug for 195 of them, across 9 drugs with 11 or more claims each, at $378,574 in total drug cost. In 2023, CMS named 154 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Mendizabal for performance year 2024, reported as part of a group. Dr. Mendizabal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mendizabal as offering telehealth.

Dmand AI links 11 papers to Dr. Mendizabal, published from 2015 to 2025. 2025 was the busiest year, with 3. Dr. Mendizabal has published most often in Curr Opin Neurol. Dr. Mendizabal's most frequent co-authors are Nicholas Abend, MD, Marissa Maliakal Anto, MD and Elizabeth Ann Felton, MD.

CMS Open Payments shows 26 general payments to Dr. Mendizabal from 4 drug and device companies from 2021 to 2025. Grants make up the largest share, 79% of the total. Medtronic, Inc. paid the most, $20,000.

Dmand AI lists 4 awards for Dr. Mendizabal, most recently Alpha Omega Alpha in 2020.

Dr. Mendizabal graduated from Lewis Katz School of Medicine in 2016. Dr. Mendizabal is a member of Alumni Board - Lewis Katz School of Medicine at Temple University, American Academy of Neurology and Leonard Davis Institute of Health Economics.

Dr. Mendizabal is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.